Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Stops Selling Generic Univasc

This article was originally published in The Pink Sheet Daily

Executive Summary

Agreement with Schwarz ends at-risk launch of the antihypertensive moexipril. Teva launched the generic in May 2003 after receiving a favorable patent ruling in federal district court.

You may also be interested in...



Teva Generic Univasc Patent Victory Vacated

Teva plans to continue distributing its generic version of Schwarz' Univasc despite an appeals court's Jan. 29 opinion vacating a noninfringement ruling for the company

What Does A Typical Refuse-To-File Letter Look Like?

Our infographic offers a composite sketch from a decade of US FDA data on refuse-to-file letters.

Pink Sheet Podcast: Dsuvia Warning Letter, Refuse-To-File Impact, CDER’s COVID Workload

Pink Sheet reporters and editor discuss the issues surrounding an FDA warning letter on Dsuvia promotion, an expected jump in CDER coronavirus-related workload, and a study of refuse-to-file actions.

Topics

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel